Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical effects of NTCP‐inhibitor myrcludex B
Dongliang Cheng, Bing Han, Wei Zhang, et al.
Journal of Viral Hepatitis (2021) Vol. 28, Iss. 6, pp. 852-858
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Acute Liver Failure Guidelines
Alexandra Shingina, Nizar A. Mukhtar, Jamilé Wakim-Fleming, et al.
The American Journal of Gastroenterology (2023) Vol. 118, Iss. 7, pp. 1128-1153
Open Access | Times Cited: 79
Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP
H Liu, Dariusz Zakrzewicz, Kamil Nosol, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
Pharmacophore modeling and QSAR analysis of anti-HBV flavonols
Basireh Baei, Parnia Askari, Fatemeh Sana Askari, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316765-e0316765
Open Access | Times Cited: 2
Structural basis of sodium-dependent bile salt uptake into the liver
Kapil Goutam, Francesco Ielasi, Els Pardon, et al.
Nature (2022) Vol. 606, Iss. 7916, pp. 1015-1020
Open Access | Times Cited: 58
The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 22
Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies
Ivana Lazarević, Ana Banko, Danijela Miljanovic, et al.
Pathogens (2024) Vol. 13, Iss. 1, pp. 46-46
Open Access | Times Cited: 8
Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
Jing Yang, Xujiao Tang, Liang Zhu, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 465-481
Open Access | Times Cited: 20
Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses
Yong He, Jiahui Zhou, Huizhan Gao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116069-116069
Closed Access | Times Cited: 16
Future applications of host direct therapies for infectious disease treatment
Ruth Thom, Riccardo V. D’Elia
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
Yan Li, Jun Zhou, Tianliang Li
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 19
Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors
Nina Komaniecka, Sonia Maroszek, Maria Droździk, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6926-6926
Open Access | Times Cited: 4
The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications
Jiangxia Du, Minhui Shen, Jiajia Chen, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor
Yixin Chen, Meitao Duan, Xiangwan Wang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107385-107385
Closed Access | Times Cited: 3
Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?
Giovana Angelice, Pedro Henrique da Conceição Roque, Guido Valente, et al.
Viruses (2024) Vol. 16, Iss. 11, pp. 1710-1710
Open Access | Times Cited: 3
Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
Takeshi Chida, Yuji Ishida, Sho Morioka, et al.
JCI Insight (2023) Vol. 8, Iss. 9
Open Access | Times Cited: 8
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA
An-Qi Zhuang, Yan Chen, Shan-Mei Chen, et al.
Viruses (2023) Vol. 15, Iss. 12, pp. 2315-2315
Open Access | Times Cited: 8
The role of HBV cccDNA in occult hepatitis B virus infection
Pei He, Peixin Zhang, Yaping Fang, et al.
Molecular and Cellular Biochemistry (2023) Vol. 478, Iss. 10, pp. 2297-2307
Closed Access | Times Cited: 7
Hepatitis B: Model Systems and Therapeutic Approaches
Xiaoxiao Yu, Yating Gao, Xin Zhang, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-15
Open Access | Times Cited: 2
The Culprit Behind HBV-Infected Hepatocytes: NTCP
Shenghao Li, Liyuan Hao, Jiali Deng, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 4839-4858
Open Access | Times Cited: 2
Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics
Zhentao Zhang, Qi Zhang, Yiwen Zhang, et al.
Biochemical Pharmacology (2023) Vol. 219, pp. 115956-115956
Closed Access | Times Cited: 6
Association between NTCP hepatic expression and inflammation/fibrosis as well as gender‐specific differences in chronic HBV‐infected patients
Jingyi Shi, Xu Wang, Wenqian Qi, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Closed Access | Times Cited: 1
SLC10A1 rs2296651 variant (S267F mutation) predicts biochemical traits, hepatitis B virus infection susceptibility and the risk of gallstone disease
Yu‐Lin Ko, Wei-Lun Tuan, Ming-Sheng Teng, et al.
Molecular Genetics and Genomics (2024) Vol. 299, Iss. 1
Closed Access | Times Cited: 1
Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity
Yan Mu, Xiaohe Ren, Di Han, et al.
Pharmaceutics (2022) Vol. 14, Iss. 7, pp. 1439-1439
Open Access | Times Cited: 7
ATP5B Is an Essential Factor for Hepatitis B Virus Entry
Keiji Ueda, Yadarat Suwanmanee
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9570-9570
Open Access | Times Cited: 7
Hepatocyte-targeting and tumor microenvironment-responsive liposomes for enhanced anti-hepatocarcinoma efficacy
Dongliang Cheng, Zhiwei Wen, Hui Chen, et al.
Drug Delivery (2022) Vol. 29, Iss. 1, pp. 2995-3008
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top